Burden of non‐motor symptoms in Parkinsons disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel

摘要

Background and purpose GLORIA, a registry conducted with 375 advanced Parkinson's disease patients treated with levodopa‐carbidopa intestinal gel (LCIG) for 24 months in routine clinical care, demonstrated significant reductions from baseline in ‘off’ time and ‘on’ time with dyskinesia and improvements in the Non‐Motor Symptom Scale (NMSS) total and individual domain scores, and in Parkinson's Disease Questionnaire 8 item (PDQ‐8) total score.